XML 63 R48.htm IDEA: XBRL DOCUMENT v3.24.4
SHARE-BASED COMPENSATION (Tables)
 12 Months Ended
Oct. 31, 2024
SHARE-BASED COMPENSATION [Abstract]  
Share-based Compensation Expenses

The table below presents information on the Company’s share-based compensation expenses for the three most recent fiscal years.


   
Year Ended
  
   
October 31,
2024
    
October 31,
2023
    
October 31,
2022
  
Expense reported in:
                  
     Cost of goods sold
  
$
2,704
    
$
1,259
    
$
868
  
     Selling, general, and administrative
    
10,124
      
5,962
      
4,803
  
     Research and development
    
1,062
      
780
      
637
  
Total expense incurred
  
$
13,890
    
$
8,001
    
$
6,308
  
                         
Expense by award type:
    
                 
Restricted stock awards *
   $
 13,868     $
 7,909     $
 5,800  
Stock options
     -       1       298  
Employee stock purchase plan
     22       91       210  
Total expense incurred
   $
 13,890
     $
 8,001
     $
 6,308
  
                         
Income tax benefits of share-based compensation
  
$
1,156
    
$
715
    
$
449
  



* During the year ended October 31, 2024, upon the departure of two executives from the Company and in accordance with the terms of their separation agreements, previously granted time-vesting restricted stock awards accelerated vesting. The Company accounted for the effects of the accelerated vesting of these stock awards as a modification, and recognized $1.2 million of incremental stock-based compensation for the acceleration of restricted stock awards, within selling, general and administrative expenses on the Consolidated Statements of Income for the year ended October 31, 2024.
Restricted Stock Awards Activity A summary of restricted stock award activity during 2024 and the status of the Company’s  restricted stock awards as of October 31, 2024, is presented below.

Restricted Stock
  
Shares
    
Weighted-Average
Fair Value at
Grant Date
  
Outstanding at October 31, 2023
    
1,238,297
    
$
16.27
  
Granted
    
865,050
    

29.50
  
Vested
    
(550,069
)
  

17.74
  
Cancelled
    
(129,676
)
  

21.90
  
Outstanding at October 31, 2024
    
1,423,602
    

23.23
  
Expected to vest as of October 31, 2024
    
1,292,883
    

23.14
  
Additional Information on Restricted Stock Awards

The table below presents additional information on the Company’s restricted stock awards for the three most recent fiscal years.


   
Year Ended
  
   
October 31,
2024
    
October 31,
2023
    
October 31,
2022
  
Number of shares granted
    
865,050
      
791,925
      
654,224
  
Weighted-average grant-date fair value of awards (in dollars per share)
  
$
29.50
    
$
16.84
    
$
18.73
  
Compensation costs not yet recognized
   $
21,303     $
 12,760     $
 8,949  
Weighted-average amortization period (in years)
     2.8       2.8       2.7  
Fair value of awards for which restrictions lapsed
  
$
9,755
    
$
6,256
    
$
5,212
  
Shares outstanding at balance sheet date
     1,423,602       1,238,297
       893,704
  
Stock Options Activity

The table below presents a summary of stock options activity during 2024 and information on stock options outstanding at October 31, 2024.

 
Shares
    
Weighted-Average
Exercise Price
  
Weighted-Average
Remaining
Contractual Life
  
Aggregate
Intrinsic Value
  
Outstanding at October 31, 2023
    
472,275
    
$
10.18
          
Granted
    
-
    
$
-
          
Exercised
    
(191,650
)
  
$
9.86
          
Cancellations, forfeitures, and adjustments
    
(3,000
)
  
$
10.43
          
Outstanding at October 31, 2024
    
277,625
    
$
10.39
  
1.94 years
  
$
3,445
  
Exercisable at October 31, 2024
    
277,625
    
$
10.39
  
1.94 years
  
$
3,445
  
Expected to vest as of October 31, 2024
    
-
    
$
-
  
- years
  
$
-
  
Additional Information on Stock Option Awards

The table below presents additional information on stock option awards for the three most recent fiscal years.


   
Year Ended
  
   
October 31,
2024
    
October 31,
2023
    
October 31,
2022
  
Number of options granted in period
     -
       -
       -
  
Total intrinsic value of options exercised
  
$
2,981
    
$
1,654
    
$
5,108
  
Cash received from option exercises
  
$
1,888
    
$
1,101
    
$
5,275
  
Compensation cost not yet recognized
   $
 -     $
 -     $
 13  
Weighted-average amortization period for cost not yet recognized (in years)
     -       -
       0.2